

A deeply reported examination into how the 2020 presidential candidates could reshape the pharmaceutical industry

STAT

Reporting from the frontiers of health and medicine

## What's inside

From the mildest moderates to the staunchest progressives, nearly every Democrat seeking the party's nomination for president next year has made drug pricing a central element of his or her campaign. This examination by STAT of the 2020 presidential election exhaustively details each candidate's plans for reforming the biopharmaceutical industry. It aims to help policy experts, industry insiders, investors, and political consultants navigate the sweeping proposals put forth by the candidates. Our reporting, in some cases, goes back years, and turns up overlooked remarks and policy from the candidates.

## The report includes:

- An executive summary that thoroughly details the candidates' campaign
  pledges. This includes the Democratic field's most aggressive policy planks,
  its sharpest rhetoric, and its history of receiving campaign funding from
  the pharmaceutical, health insurance, and medical device industries.
- Expert opinions and analysis from a range of STAT's journalists in D.C. and around the country, including my fellow Washington correspondent Nicholas Florko and me, Washington editor Erin Mershon, and senior writer Ed Silverman.
- An essay about the 2020 election's likely impact on the pharmaceutical industry by senior writer Matt Herper.

- A Q&A between Democratic strategist and former senior Obama administration adviser David Axelrod and our executive editor, Rick Berke, who for more than a decade was the chief political correspondent of the New York Times.
- A comprehensive graphic that directly compares the candidates' positions on key policies aimed at lowering the cost of prescription drugs.
- Analysis of the 2020 candidates' histories and campaign infrastructure related to drug pricing policies, broken into three separate groups determined by current polling averages and political dynamics: front-runners, mid-tier candidates, and long-shot candidates.
- Similar analysis of the Democratic candidates who have already exited the race, since many continue to serve in Congress or as governors, and could potentially be future vice presidential candidates or cabinet members.
- Information about the major pharmaceutical interests that many Democratic candidates represent in their home states or districts.
- Suggested additional reading about each candidate.

It also includes details about past positions and key staffers for each candidate in the four tiers, listed in the table of contents and ordered based on the RealClear-Politics polling index for the 2020 Democratic primary as of late September 2019.

Lev Facher

LW Faden

Washington Correspondent, STAT

## **Table of Contents**

01	EXECUTIVE SUMMARY	41	MID-TIER CANDIDATES
01	Overview	42	Pete Buttigieg
04	Candidates	46	Kamala Harris
06	President Trump	52	Andrew Yang
07	The Policies the Democrats Support	55	Cory Booker
10	Medicare for All	60	Amy Klobuchar
10	The Opioid Crisis	65	Julián Castro
11	Congress		
12	Campaign Finance	68	LONG-SHOT CANDIDATES
14	Public Opinion	69	Tulsi Gabbard
		70	Michael Bennet
15	EXCLUSIVE Q&A	71	Tom Steyer
	Between Democratic strategist and	73	John Delaney
	former senior Obama administration adviser David Axelrod and STAT	75	Steve Bullock
	executive editor, Rick Berke	77	Marianne Williamson
		79	Joe Sestak
18	CANDIDATES STANCES ON DRUG PRICING	80	Wayne Messam
		81	CANDIDATES WHO HAVE DROPPED OUT
19	FOREWORD	82	Kirsten Gillibrand
	By Matthew Herper, STAT senior medicine writer	84	Jay Inslee
		86	Bill de Blasio
21	FRONT-RUNNER CANDIDATES	88	Seth Moulton
22	Joe Biden	89	Richard Ojeda
28	Elizabeth Warren	90	Tim Ryan
34	Bernie Sanders	92	Beto O'Rourke